Insilico Medicine climbs 6%

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Insilico Medicine (3696.HK) climbed more than 6% in Hong Kong trading to HK$39.74.

The stock is up 8.66% over the past ten sessions, down 38.32% over the past six months and up 6.79% year to date. It sits 32.56% above its 52-week low of HK$29.98.

The Hang Seng Index is up 5.39% over the past five sessions and down 3.81% year to date.

The life sciences tools and services industry index rose 3.7% over the same period.

The company plans to invest about 303 million yuan to co-establish a biopharmaceutical investment fund with a target size of 1.01 billion yuan, focusing on growth-stage companies in biomedicine, life sciences and artificial intelligence.

Separately, Insilico announced a share buyback program of up to HK$500 million in the open market, noting that it believes the current share price undervalues its intrinsic value. Phase I clinical data for its AI-designed drug ISM6331, presented at the ESMO congress, showed an objective response rate of 40% in the 130mg mesothelioma cohort.

Based on public media reports. AI-generated; not investment advice.

Source: Market Movers The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.